These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6622889)

  • 41. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.
    Kendal AP; Bozeman FM; Ennis FA
    Infect Immun; 1980 Sep; 29(3):966-71. PubMed ID: 7429641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cellular response in humans following vaccination with Gripax influenza virus.
    Shapira-Nahor O; Morag A; Levy R; Zakay-Rones Z
    J Med Virol; 1982; 10(1):75-80. PubMed ID: 7130968
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An attenuated influenza virus vaccine: protection against homologous and heterologous strains of virus.
    Khakoo R; Ganguly R; Waldman R
    Dev Biol Stand; 1977 Jun 1-3; 39():141-8. PubMed ID: 342305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity.
    Clark A; Potter CW; Jennings R; Nicholl JP; Langrick AF; Schild GC; Wood JM; Tyrrell DA
    J Hyg (Lond); 1983 Jun; 90(3):351-9. PubMed ID: 6863909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of one- and two-dose regimens of influenza vaccine for elderly men.
    Levine M; Beattie BL; McLean DM
    CMAJ; 1987 Oct; 137(8):722-6. PubMed ID: 3651943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
    Precioso AR; Miraglia JL; Campos LM; Goulart AC; Timenetsky Mdo C; Cardoso MR; Luna E; Mondini G; Guedes Jda S; Raw I
    Vaccine; 2011 Nov; 29(48):8974-81. PubMed ID: 21945258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The antigenicity of whole virus versus subunit trivalent influenza vaccines -- a field trial in the Israel Defence Forces, 1978.
    Kark JD; Lebiush M; Rannon L; Witztum E; Nili E; Kedem R
    Med Microbiol Immunol; 1981; 170(1):55-62. PubMed ID: 7029236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children.
    Zangwill KM; Droge J; Mendelman P; Marcy SM; Partridge S; Chiu CY; Jing J; Chang SJ; Cho I; Ward JI
    Pediatr Infect Dis J; 2001 Aug; 20(8):740-6. PubMed ID: 11734734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: reactogenicity, immunogenicity and persistence of antibodies following two doses of vaccines.
    Ochiai H; Shibata M; Kamimura K; Niwayama S
    Microbiol Immunol; 1986; 30(11):1141-9. PubMed ID: 3807793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A clinical trial with Alice/R-75 strain, live attenuated serum inhibitor-resistant intranasal bivalent influenza A/B vaccine.
    Spencer MJ; Cherry JD; Powell KR; Sumaya CV
    Med Microbiol Immunol; 1979 Mar; 167(1):1-9. PubMed ID: 375050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination.
    Manenti A; Tete SM; Mohn KG; Jul-Larsen Å; Gianchecchi E; Montomoli E; Brokstad KA; Cox RJ
    Vaccine; 2017 Jan; 35(1):191-198. PubMed ID: 27789145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
    AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative trial of influenza vaccines. I. Immunogenicity of whole virus and split product vaccines in man.
    Barry DW; Mayner RE; Staton E; Dunlap RC; Rastogi SC; Hannah JE; Blackburn RJ; Nortman DF; Graze PR
    Am J Epidemiol; 1976 Jul; 104(1):34-46. PubMed ID: 947145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative antigenicity and immunogenicity of A/USSR/77 influenza vaccines in normal and primed mice.
    McLaren C; Grubbs GE; Staton E; Barthlow W; Quinnan G; Ennis FA
    Infect Immun; 1980 Apr; 28(1):171-7. PubMed ID: 7380562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults.
    Sears SD; Clements ML; Betts RF; Maassab HF; Murphy BR; Snyder MH
    J Infect Dis; 1988 Dec; 158(6):1209-19. PubMed ID: 3198936
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine.
    Johnson PR; Feldman S; Thompson JM; Mahoney JD; Wright PF
    J Med Virol; 1985 Dec; 17(4):325-35. PubMed ID: 4078559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1).
    Schmidt S; Süss J; Oehring H; Schmidt J
    Acta Virol; 1982 Dec; 26(6):466-73. PubMed ID: 6132540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults.
    Keitel WA; Couch RB; Quarles JM; Cate TR; Baxter B; Maassab HF
    J Infect Dis; 1993 Feb; 167(2):305-11. PubMed ID: 8421165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
    N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults.
    Frey S; Poland G; Percell S; Podda A
    Vaccine; 2003 Oct; 21(27-30):4234-7. PubMed ID: 14505903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.